Meyron

Reference summary — not medical advice or a personal risk estimate.

Azathioprine

Group 1 — carcinogenic to humansMedications & MedicalbehavioralEvidence: sufficient_in_humans

Summary

An immunosuppressive medication used after organ transplant. Associated with non-Hodgkin lymphoma and skin cancer.

Detail

Azathioprine is Group 1 with sufficient evidence for non-Hodgkin lymphoma and non-melanoma skin cancer. Used after organ transplant and for some autoimmune conditions. Transplant recipients as a group have increased risks of several cancers (the immunosuppression itself is the carcinogenic exposure). Questions about whether azathioprine is appropriate are clinical decisions between a patient and their care team.

Regional relevance

global

global

Documented in these products

Presence in a product category doesn't imply the product causes cancer. Click each to see the source and context.

Sources

Consumer references

Third-party tools some readers use alongside primary evidence. Meyron doesn't endorse them; we link them because you'll otherwise hit them anyway.